Home Cart Sign in  
Chemical Structure| 1492952-76-7 Chemical Structure| 1492952-76-7

Structure of Asciminib
CAS No.: 1492952-76-7

Chemical Structure| 1492952-76-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Asciminib is a potent and selective allosteric Bcr-Abl inhibitor and inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.

Synonyms: ABL001

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Asciminib

CAS No. :1492952-76-7
Formula : C20H18ClF2N5O3
M.W : 449.84
SMILES Code : O=C(NC1=CC=C(OC(F)(Cl)F)C=C1)C2=CN=C(N3C[C@H](O)CC3)C(C4=NNC=C4)=C2
Synonyms :
ABL001
MDL No. :MFCD31560488
InChI Key :VOVZXURTCKPRDQ-CQSZACIVSA-N
Pubchem ID :72165228

Safety of Asciminib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Asciminib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
KMS-12-PE cells 10 μM 24 hours significantly induced apoptosis PMC9786043
KMS-12-PE cells 10 μM 4 hours induced XBP1 mRNA splicing PMC9786043
K562 8.1 nM 72 hours To evaluate the growth inhibitory effect of Asciminib on K562 cells, the results showed that Asciminib significantly inhibited the growth of K562 cells with an IC50 of 8.1 nM PMC6893878
LAMA84 3.2 nM 72 hours To evaluate the growth inhibitory effect of Asciminib on LAMA84 cells, the results showed that Asciminib significantly inhibited the growth of LAMA84 cells with an IC50 of 3.2 nM PMC6893878
Ba/F3 BCR-ABL1 3.8 nM 72 hours To evaluate the proliferation inhibitory effect of Asciminib on Ba/F3 BCR-ABL1 cells, the results showed that Asciminib significantly inhibited the proliferation of Ba/F3 BCR-ABL1 cells with an IC50 of 3.8 nM PMC6893878
K-562R cells 3 µM 72 hours To evaluate the synergistic effect of Asciminib with MAC681, results showed that 3 μM MAC681 with 1, 10, and 30 μM Asciminib exhibited synergistic effects in K-562R cells over 72 hours. PMC11069214
K-562 cells 3 µM 72 hours To evaluate the synergistic effect of Asciminib with MAC681, results showed that 3 μM MAC681 with 1, 10, and 30 μM Asciminib exhibited synergistic effects in K-562 cells over 72 hours. PMC11069214
T cells 1.25, 5, 10 µM 72 hours Effects of Asciminib on T cell activation and metabolic fitness, showing milder inhibitory effects on T cell activation, which might be beneficial for the immunological control of residual CML cells. PMC10198838

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nod-SCID mice BCR-ABL1T315I/H396R leukemia model Oral 30 mg/kg Once daily for 19 days To evaluate the efficacy of the combination of Asciminib and Ponatinib in the BCR-ABL1T315I/H396R leukemia model, the results showed that the combination treatment significantly prolonged survival and inhibited tumor growth PMC6893878
Mice CML-BC cell line-derived xenograft model Oral 30 mg/kg once daily for 8 days, then intermittent dosing until day 16 Evaluate the antitumor effect of Asciminib in combination with Ponatinib, significantly suppressing tumor growth and prolonging survival PMC11147753

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04360005 Chronic Myeloid Leukemia in Ch... More >>ronic Phase Less << AVAILABLE - -
NCT04216563 Philadelphia Chromosome Negati... More >>ve, BCR-ABL1 Positive Chronic Myelogenous Leukemia Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-12-31 M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less <<
NCT06427811 Philadelphia Chromosome-Positi... More >>ve Chronic Myeloid Leukemia in Chronic Phase Less << PHASE4 NOT_YET_RECRUITING 2025-04-23 -
NCT06236724 Chronic Myeloid Leukemia PHASE2 RECRUITING 2035-07-01 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<
NCT03605277 Renal Impairment PHASE1 COMPLETED 2019-04-14 Novartis Investigative Site, S... More >>ofia, 1612, Bulgaria|Novartis Investigative Site, Berlin, 14050, Germany Less <<
NCT06629584 Malignant Solid Tumors PHASE2 NOT_YET_RECRUITING 2028-12-31 The University of Texas MD And... More >>erson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT06368414 Chronic Myeloid Leukemia, Chro... More >>nic Phase Less << PHASE2 NOT_YET_RECRUITING 2028-08-31 -
NCT02857868 Hepatic Impairment PHASE1 COMPLETED 2017-07-20 University of Miami / Clinical... More >> Research Services, Inc., Miami, Florida, 33136, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States Less <<
NCT04666259 Chronic Myelogenous Leukemia -... More >> Chronic Phase Less << PHASE3 COMPLETED 2024-06-26 Alaska Oncology and Hematology... More >> AOH 2, Anchorage, Alaska, 99508, United States|Cancer Treatment Centers of America, Phoenix, Arizona, 85027, United States|Pacific Shores Medical Group, Long Beach, California, 90813, United States|Lundquist Inst BioMed at Harbor ., Torrance, California, 90509-2910, United States|Rocky Mountain Cancer Centers USOR, Boulder, Colorado, 80304, United States|Memorial Healthcare System ., Hollywood, Florida, 33021, United States|Florida Cancer Specialists-North, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists East, Stuart, Florida, 34994, United States|Indiana Blood and Marrow Institute ., Beech Grove, Indiana, 46107, United States|University of Kentucky, Lexington, Kentucky, 40536, United States|Uni of Massachusetts Medical Center, Worcester, Massachusetts, 01655, United States|Michigan Med University of Michigan ., Ann Arbor, Michigan, 48109 5271, United States|Siteman Cancer Center ., Saint Louis, Missouri, 63110, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Wake Forest Uni Baptist MC Outpatient Comprehensive Can C, Winston-Salem, North Carolina, 27157, United States|Uni of Cincinnati Medical Center ., Cincinnati, Ohio, 45219, United States|Oncology Hematology Care Inc ., Cincinnati, Ohio, 45242, United States|Northwest Cancer Specialists HematologyCln ProvidenceOffice, Portland, Oregon, 97210, United States|Texas Oncology ., Dallas, Texas, 75251, United States|Texas Oncology, P.A. ., Fort Worth, Texas, 76104, United States|Univ of TX MD Anderson Cancer Cntr ., Houston, Texas, 77030, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.22mL

0.44mL

0.22mL

11.12mL

2.22mL

1.11mL

22.23mL

4.45mL

2.22mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories